Iloprost

Spécifications

78919-13-8Numéro CAS

636-055-8Numéro CE

(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acidNom IUPAC

C22H32O4Formule chimique

360.5 g/molMasse molaire

ILOPROST; 78919-13-8; Ciloprost; Ventavis; Endoprost; Ilomedin; Aurlumyn; Iloprostum; ZK-36374; DTXSID2041046; JED5K35YGL; ZK 36374; ZK 00036374; CHEBI:63916; ZK-00036374; DTXCID001333799; (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid; Pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-; (E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid; PENTANOIC ACID, 5-((3AS,4R,5R,6AS)-HEXAHYDRO-5-HYDROXY-4-((1E,3S)-3-HYDROXY-4-METHYL-1-OCTEN-6-YNYL)-2(1H)-PENTALENYLIDENE)-, (5E)-; ZK36374; Iloprost Clathrate; (5E)-(3AS,4R,5R,6AS)-5-HYDROXY-4-((1E)-(3S,4RS)-3-HYDROXY-4-METHYLOCT-1-EN-6-YNYL)-HEXAHYDROPENTALEN-2(1H)-YLIDENE)PENTANOIC ACID; (5E)-[3aS,4R,5R,6aS)-5-Hydroxy-4-[(1E)-(3S,4RS)-3-hydroxy-4-methyloct-1-en-6-ynyl]-hexahydropentalen-2(1H)-ylidene]pentanoic acid; (5E)-5-((3aS,4R,5R,6aS)-5-hydroxy-4-((1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid; RefChem:56820; B01AC11; (5E)-5-((3aS,5R,6aS)-5-hydroxy-4-((E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl)-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene)pentanoic acid; CHEMBL494; (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; 5-cis Iloprost; [3H]-Iloprost; Ventavis (TN); 73873-87-7; (16R,S)-methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I2; 5-[(2E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid; Iloprostum [Latin]; SR-05000001498; UNII-JED5K35YGL; Iloprost [USAN:INN:BAN]; Cilaprost; Ilomedine; BAY Q6256; NCGC00181784-01; Iloprost (Standard); ILOPROST [USAN]; Iloprost (USAN/INN); ILOPROST [INN]; ILOPROST [JAN]; ILOPROST [MI]; ILOPROST [VANDF]; ILOPROST [MART.]; ILOPROST [WHO-DD]; ILOPROST [EMA EPAR]; ILOPROST [ORANGE BOOK]; orb1707189; SCHEMBL6083382; Iloprost, >=98% (HPLC); BAY-q-6256; BDBM23954; HY-A0096R; HIFJCPQKFCZDDL-ACWOEMLNSA-N; GLXC-10328; HMS2090A19; EX-A6213; HY-A0096; Tox21_113586; EBC-26789; SH-401; (16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2); AKOS024456922; CS-5586; DB01088; FH24541; (5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyl-oct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid; (E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure; MS-25711; CAS-78919-13-8; D02721; E-1030; EN300-21702615; F979607; I458579; SR-05000001498-1; SR-05000001498-2; BRD-A45664787-001-01-4; BRD-A45664787-001-02-2; BRD-A45664787-001-04-8; Q20817139; 6,9alpha-methylene-11alpha,15S-dihydroxy-16-methyl-prosta-5Z,13E-dien-18-yn-1-oic acid; (1S,2R,3R,5S)-7-[(E)-4-Carboxybutyl idene]-2-[(3S ,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-bicyclo[3.3.0]octane; (1S,2R,3R,5S)-7-[(E)-4-carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane; 5-((3aS,4R,5R,6aS,E)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid; 5-Hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pental enylidene)pentanoic acidSynonymes